Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

Antiviral therapy - 1 Jan 2008

Dunn David, Geretti Anna Maria, Green Hannah, Fearnhill Esther, Pozniak Anton, Churchill Duncan, Pillay Deenan, Sabin Caroline, Phillips Andrew

Abstract excerpt

BACKGROUND: In recent years, several new drugs from the protease inhibitor (PI) class designed to treat HIV infection have become available and the use of ritonavir-boosting has increased in popularity. These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure. METHODS: The UK HIV Drug Resistance Database aims to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Sectional Studies
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Ritonavir

Share to United Kingdom

Source

Identifiers

PMID: 18839778

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.PMID 18839778Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.Semantic proximity Read ↗

Resistance to protease inhibitors.Semantic proximity Read ↗

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.Semantic proximity Read ↗

A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.Semantic proximity Read ↗

Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.Semantic proximity Read ↗

Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational studySemantic proximity Read ↗

Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.Semantic proximity Read ↗

Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.Semantic proximity Read ↗

Hiv-1 Gag Gene Mutations, Treatment Response and Drug Resistance to Protease Inhibitors: A Systematic Review and Meta-analysis ProtocolSemantic proximity Read ↗

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.